Profile data is unavailable for this security.
About the company
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
- Revenue in SEK (TTM)638.60m
- Net income in SEK-128.40m
- Incorporated1994
- Employees116.00
- LocationOrexo ABRapsgatan 7EUPPSALA 751 05SwedenSWE
- Phone+46 187808800
- Fax+46 187808888
- Websitehttps://orexo.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INIFY Laboratories AB | 3.42m | -51.44m | 420.55m | 23.00 | -- | 5.75 | -- | 122.90 | -1.14 | -1.14 | 0.0761 | 1.63 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -101.62m | 477.91m | 30.00 | -- | 0.5812 | -- | -- | -0.2554 | -0.2554 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.72m | 486.27m | 3.00 | -- | 27.66 | -- | -- | -0.6573 | -0.6573 | 0.00 | 0.3322 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Promimic AB | 37.07m | -9.22m | 542.93m | 17.00 | -- | 7.08 | -- | 14.65 | -0.5295 | -0.5295 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.88 | -11.67 | -29.25 | 103.90 | 101.23 | -24.87 | -89.46 | 3.98 | -- | -- | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Bergenbio ASA | 352.04k | -189.35m | 553.52m | 18.00 | -- | 3.00 | -- | 1,572.32 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 566.96m | 18.00 | -- | 6.76 | -- | 11.99 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| IRLAB Therapeutics AB | 5.68m | -177.84m | 567.09m | 37.00 | -- | 4.91 | -- | 99.87 | -3.43 | -3.43 | 0.1095 | 2.23 | 0.0227 | -- | 0.5137 | -- | -71.04 | -27.12 | -82.41 | -30.42 | -2,161.57 | -72.18 | -3,132.07 | -155.57 | -- | -- | 0.1923 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Gentian Diagnostics ASA | 134.41m | -10.59m | 592.01m | 58.00 | -- | 4.06 | -- | 4.40 | -0.6905 | -0.6905 | 8.76 | 9.51 | 0.7329 | 1.76 | 7.47 | 2,330,224.00 | -5.77 | -10.76 | -6.62 | -11.86 | 50.61 | 41.46 | -7.88 | -26.99 | 4.13 | -- | 0.0817 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Cantargia AB | 0.00 | -280.03m | 627.84m | 22.00 | -- | 3.72 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
| Oncopeptides AB | 35.22m | -249.11m | 628.86m | 57.00 | -- | 6.66 | -- | 17.86 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Orexo AB | 638.60m | -128.40m | 633.12m | 116.00 | -- | 10.67 | -- | 0.9914 | -3.73 | -3.73 | 18.55 | 1.71 | 0.6738 | 1.52 | 2.88 | 5,505,173.00 | -13.55 | -6.41 | -20.60 | -9.99 | 86.09 | 86.76 | -20.11 | -11.83 | 1.58 | 0.3604 | 0.8894 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| Alligator Bioscience AB | 58.11m | -248.59m | 695.12m | 58.00 | -- | 50.97 | -- | 11.96 | -0.5613 | -0.5613 | 0.1205 | 0.018 | 0.4035 | -- | 8.34 | 1,001,845.00 | -172.61 | -73.26 | -399.57 | -91.33 | -- | -- | -427.81 | -811.68 | -- | -- | 0.5759 | -- | 62.78 | 16.60 | -28.53 | -- | -20.34 | -- |
| Intellego Technologies AB | 186.49m | 59.61m | 751.05m | 68.00 | 12.06 | 4.97 | 11.90 | 4.03 | 2.36 | 2.36 | 7.43 | 5.74 | 0.8841 | 3.26 | 3.69 | 2,742,544.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 1.97 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| BioPorto A/S | 48.35m | -87.97m | 783.86m | 31.00 | -- | 8.34 | -- | 16.21 | -0.1605 | -0.1605 | 0.0883 | 0.1585 | 0.312 | 3.40 | 11.96 | 998,645.20 | -56.77 | -71.10 | -79.27 | -96.55 | 65.19 | 63.38 | -181.95 | -239.22 | 3.09 | -1,718.97 | 0.1076 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Nightingale Health Oyj | 42.55m | -210.30m | 806.39m | 81.00 | -- | 1.18 | -- | 18.95 | -0.2979 | -0.2979 | 0.0603 | 1.50 | 0.0344 | 1.60 | 3.87 | 44,560.98 | -17.02 | -14.20 | -18.12 | -15.69 | 75.81 | 83.57 | -494.25 | -408.50 | 14.15 | -- | 0.0378 | -- | 80.80 | 19.05 | -12.38 | -- | -- | -- |
Data as of May 03 2024. Currency figures normalised to Orexo AB's reporting currency: Swedish Krona SEK
10.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ATP Arbejdsmarkedets Till�gspensionas of 31 Aug 2023 | 1.78m | 5.13% |
| Lancelot Asset Management ABas of 30 Jun 2020 | 500.00k | 1.44% |
| Sj�tte AP-fondenas of 31 Dec 2022 | 390.93k | 1.13% |
| Handelsbanken Fonder ABas of 31 Aug 2023 | 187.01k | 0.54% |
| Consultinvest Asset Management SGR SpAas of 31 Aug 2023 | 176.45k | 0.51% |
| SEB Investment Management ABas of 28 Mar 2024 | 165.98k | 0.48% |
| Skandia Investment Management ABas of 29 Feb 2024 | 136.46k | 0.39% |
| UBS AG (Private Banking)as of 31 Dec 2021 | 55.00k | 0.16% |
| Nordic Archipelago Investments ABas of 30 Jun 2022 | 52.00k | 0.15% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 39.89k | 0.12% |
More ▼
Data from 31 Dec 2021 - 31 Mar 2024Source: FactSet Research Systems Inc.
